Abbott Laboratories Corporation

Catherine M McCarty

Andrew O Stewart

Meena V Patel

Lawrence A Black

Teodozyj Kolasa

Michael E Kort

Huaqing Liu

Anwer Basha

Jeffrey J Rohde

Michael J Coghlan

Steven Armen Boyd

Gui-Dong Zhu

Pramila A Bhatia

David M Stout

David L Arendsen

Nicholas A Mort

Indrani W Gunawardana

Michael A Staeger

Jennifer C Freeman

Kraig Lartey

Kevin R Condroski

The present invention describes pyridazinone compounds of formula I which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2), COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important 'housekeeping' enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently markered non-steroidal anti-inflammatory drugs (NSAIDs).

Prostaglandin endoperoxide H synthase biosynthesis inhibitors

The present invention describes pyridazinone compounds of formula Iwhich are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important 'housekeeping' enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).

Cell adhesion-inhibiting antiinflammatory compounds

The present invention describes pyridazinone compounds of formula I

Growing community of inventors

Brookline, MA, United States of America

Catherine M McCarty